サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1654208

脳梗塞治療の市場規模、シェア、動向分析レポート：薬剤クラス別、タイプ別、流通チャネル別、地域別、セグメント予測、2025年～2030年

Cerebral Infarction Treatment Market Size, Share & Trends Analysis Report By Drug Class (Anticoagulants, Antiplatelets), By Type (Ischemic Stroke), By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030

出版日
ページ情報
英文 100 Pages
納期
2～10営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.06円
脳梗塞治療の市場規模、シェア、動向分析レポート：薬剤クラス別、タイプ別、流通チャネル別、地域別、セグメント予測、2025年～2030年
出版日: 2025年01月15日
発行: Grand View Research
ページ情報: 英文 100 Pages
納期: 2～10営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

脳梗塞治療市場の成長と動向：

Grand View Research, Inc.の最新レポートによると、世界の脳梗塞治療市場規模は2030年までに205億1,000万米ドルに達すると予測され、2025年から2030年までのCAGRは7.4%で成長すると予測されています。

世界人口の高齢化と高血圧や糖尿病などの生活習慣関連危険因子の増加によって虚血性脳卒中の有病率が増加していることが、脳梗塞治療市場拡大の主要因となっています。

米国国立医学図書館が2023年3月に発表した研究によると、出血性脳梗塞は年間全脳卒中の10.0～20.0％を占める。発症率は地域によって大きく異なり、米国、英国、オーストラリアでは8.0～15.0％、日本と韓国では18.0～24.0％となっています。出血性脳卒中の発症率は、低・中所得国とアジア人で顕著に高いです。さらに、脳卒中発症率は男性で高く、年齢とともに増加しますが、出血性脳卒中の世界の負担は、特にアフリカやアジア諸国で増加しています。高血圧の効果的な管理により脳内出血（ICH）の発症率が低下することが示されていますが、致死率は依然として懸念されており、高所得国では25.0～30.0％、低所得地域では30～48％であり、クリティカルケアの有効性に格差があることが浮き彫りになっています。

技術の進歩は、脳梗塞の治療状況を著しく向上させています。組織プラスミノーゲン活性化因子（tPA）などの血栓溶解療法の革新や機械的血栓除去装置の開発は、患者の転帰を著しく改善しました。さらに、診断・治療プロセスへの人工知能（AI）の統合は、脳卒中治療に革命をもたらしています。AI主導のアルゴリズムは現在、脳卒中リスクの予測や治療戦略の調整において重要な役割を果たしており、治療の個別化や全体的な有効性の向上に役立っています。こうした進歩は、治療の精度を向上させるだけでなく、先進的な治療法の幅広い導入にも貢献しています。研究開発への投資の増加と相まって、こうした技術的進歩が脳梗塞治療市場の大きな成長を促進すると期待されています。

脳梗塞治療市場のレポートハイライト

  • 2024年、虚血性脳卒中分野は、その高い有病率、技術の進歩、早期介入への意識の高まりにより、78.6%の最大シェアを占めました。
  • 組織プラスミノーゲン活性化因子（tPA）セグメントは、その実証された有効性、広範な使用、虚血性脳卒中治療における重要な役割により、2024年に39.2％の最大収益シェアを確保しました。
  • 2024年には、病院薬局部門が脳梗塞治療市場を独占し、63.6％の大幅な売上シェアを獲得しました。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 脳梗塞治療市場の変数、動向、範囲

  • 市場系統の見通し
  • 市場力学
    • 市場ドライバー分析
    • 市場抑制要因分析
  • ビジネス環境分析
    • 業界分析- ポーターのファイブフォース分析
    • PESTLE分析

第4章 脳梗塞治療市場：薬剤クラスビジネス分析

  • 薬物クラス市場シェア、2024年および2030年
  • 薬物クラスセグメントダッシュボード
  • 市場規模と予測および動向分析、薬剤クラス別、2018～2030年
  • 組織プラスミノーゲン活性化因子（tPA）
  • 抗凝固薬
  • 抗血小板薬
  • 抗けいれん薬
  • その他

第5章 脳梗塞治療市場：タイプ別ビジネス分析

  • タイプ別市場シェア、2024年と2030年
  • タイプセグメントダッシュボード
  • 市場規模と予測および動向分析、タイプ別、2018～2030年
  • 虚血性脳卒中
  • 出血性脳卒中

第6章 脳梗塞治療市場：流通チャネルビジネス分析

  • 流通チャネル市場シェア、2024年および2030年
  • 流通チャネルセグメントダッシュボード
  • 市場規模と予測および動向分析、流通チャネル別、2018～2030年
  • 病院薬局
  • 小売薬局
  • その他

第7章 脳梗塞治療市場：地域別推定・動向分析

  • 地域別市場シェア分析、2024年および2030年
  • 地域市場ダッシュボード
  • 市場規模と予測動向分析、2018年から2030年：
  • 北米
    • 国別
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • 国別
    • 英国
    • ドイツ
    • フランス
    • イタリア
    • スペイン
    • デンマーク
    • スウェーデン
    • ノルウェー
  • アジア太平洋
    • 日本
    • 中国
    • インド
    • 韓国
    • オーストラリア
    • タイ
  • ラテンアメリカ
    • 国別
    • ブラジル
    • アルゼンチン
  • 中東・アフリカ
    • 国別
    • 南アフリカ
    • サウジアラビア
    • アラブ首長国連邦
    • クウェート

第8章 競合情勢

  • 参加者概要
  • 企業の市況分析
  • 企業分類
  • 戦略マッピング
  • 企業プロファイル/上場企業
    • Amgen Inc.
    • Pfizer Inc.
    • Novartis AG
    • Amneal Pharmaceuticals LLC
    • Sanofi
    • Abbott
    • Johnson &Johnson Services, Inc.
    • Bristol-Myers Squibb Company
    • DAIICHI SANKYO COMPANY
    • Otsuka Holdings Co., Ltd.
図表

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 Global cerebral infarction treatment market, by region, 2018 - 2030 (USD Billion)
  • Table 4 Global cerebral infarction treatment market, by drug class, 2018 - 2030 (USD Billion)
  • Table 5 Global cerebral infarction treatment market, by type, 2018 - 2030 (USD Billion)
  • Table 6 Global cerebral infarction treatment market, by distribution channel, 2018 - 2030 (USD Billion)
  • Table 7 North America cerebral infarction treatment market, by country, 2018 - 2030 (USD Billion)
  • Table 8 North America cerebral infarction treatment market, by drug class, 2018 - 2030 (USD Billion)
  • Table 9 North America cerebral infarction treatment market, by type, 2018 - 2030 (USD Billion)
  • Table 10 North America cerebral infarction treatment market, by distribution channel, 2018 - 2030 (USD Billion)
  • Table 11 U.S. cerebral infarction treatment market, by drug class, 2018 - 2030 (USD Billion)
  • Table 12 U.S. cerebral infarction treatment market, by type, 2018 - 2030 (USD Billion)
  • Table 13 U.S. cerebral infarction treatment market, by distribution channel, 2018 - 2030 (USD Billion)
  • Table 14 Canada cerebral infarction treatment market, by drug class, 2018 - 2030 (USD Billion)
  • Table 15 Canada cerebral infarction treatment market, by type, 2018 - 2030 (USD Billion)
  • Table 16 Canada cerebral infarction treatment market, by distribution channel, 2018 - 2030 (USD Billion)
  • Table 17 Mexico cerebral infarction treatment market, by drug class, 2018 - 2030 (USD Billion)
  • Table 18 Mexico cerebral infarction treatment market, by type, 2018 - 2030 (USD Billion)
  • Table 19 Mexico cerebral infarction treatment market, by distribution channel, 2018 - 2030 (USD Billion)
  • Table 20 Europe cerebral infarction treatment market, by country, 2018 - 2030 (USD Billion)
  • Table 21 Europe cerebral infarction treatment market, by drug class, 2018 - 2030 (USD Billion)
  • Table 22 Europe cerebral infarction treatment market, by type, 2018 - 2030 (USD Billion)
  • Table 23 Europe cerebral infarction treatment market, by distribution channel, 2018 - 2030 (USD Billion)
  • Table 24 UK cerebral infarction treatment market, by drug class, 2018 - 2030 (USD Billion)
  • Table 25 UK cerebral infarction treatment market, by type, 2018 - 2030 (USD Billion)
  • Table 26 UK cerebral infarction treatment market, by distribution channel, 2018 - 2030 (USD Billion)
  • Table 27 Germany cerebral infarction treatment market, by drug class, 2018 - 2030 (USD Billion)
  • Table 28 Germany cerebral infarction treatment market, by type, 2018 - 2030 (USD Billion)
  • Table 29 Germany cerebral infarction treatment market, by distribution channel, 2018 - 2030 (USD Billion)
  • Table 30 France cerebral infarction treatment market, by drug class, 2018 - 2030 (USD Billion)
  • Table 31 France cerebral infarction treatment market, by type, 2018 - 2030 (USD Billion)
  • Table 32 France cerebral infarction treatment market, by distribution channel, 2018 - 2030 (USD Billion)
  • Table 33 Italy cerebral infarction treatment market, by drug class, 2018 - 2030 (USD Billion)
  • Table 34 Italy cerebral infarction treatment market, by type, 2018 - 2030 (USD Billion)
  • Table 35 Italy cerebral infarction treatment market, by distribution channel, 2018 - 2030 (USD Billion)
  • Table 36 Spain cerebral infarction treatment market, by drug class, 2018 - 2030 (USD Billion)
  • Table 37 Spain cerebral infarction treatment market, by type, 2018 - 2030 (USD Billion)
  • Table 38 Spain cerebral infarction treatment market, by distribution channel, 2018 - 2030 (USD Billion)
  • Table 39 Denmark cerebral infarction treatment market, by drug class, 2018 - 2030 (USD Billion)
  • Table 40 Denmark cerebral infarction treatment market, by type, 2018 - 2030 (USD Billion)
  • Table 41 Denmark cerebral infarction treatment market, by distribution channel, 2018 - 2030 (USD Billion)
  • Table 42 Sweden cerebral infarction treatment market, by drug class, 2018 - 2030 (USD Billion)
  • Table 43 Sweden cerebral infarction treatment market, by type, 2018 - 2030 (USD Billion)
  • Table 44 Sweden cerebral infarction treatment market, by distribution channel, 2018 - 2030 (USD Billion)
  • Table 45 Norway cerebral infarction treatment market, by drug class, 2018 - 2030 (USD Billion)
  • Table 46 Norway cerebral infarction treatment market, by type, 2018 - 2030 (USD Billion)
  • Table 47 Norway cerebral infarction treatment market, by distribution channel, 2018 - 2030 (USD Billion)
  • Table 48 Asia Pacific cerebral infarction treatment market, by country, 2018 - 2030 (USD Billion)
  • Table 49 Asia Pacific cerebral infarction treatment market, by drug class, 2018 - 2030 (USD Billion)
  • Table 50 Asia Pacific cerebral infarction treatment market, by type, 2018 - 2030 (USD Billion)
  • Table 51 Asia Pacific cerebral infarction treatment market, by distribution channel, 2018 - 2030 (USD Billion)
  • Table 52 Japan cerebral infarction treatment market, by drug class, 2018 - 2030 (USD Billion)
  • Table 53 Japan cerebral infarction treatment market, by type, 2018 - 2030 (USD Billion)
  • Table 54 Japan cerebral infarction treatment market, by distribution channel, 2018 - 2030 (USD Billion)
  • Table 55 China cerebral infarction treatment market, by drug class, 2018-2030 (USD Billion)
  • Table 56 China cerebral infarction treatment market, by type, 2018-2030 (USD Billion)
  • Table 57 China cerebral infarction treatment market, by distribution channel, 2018-2030 (USD Billion)
  • Table 58 India cerebral infarction treatment market, by drug class, 2018 - 2030 (USD Billion)
  • Table 59 India cerebral infarction treatment market, by type, 2018 - 2030 (USD Billion)
  • Table 60 India cerebral infarction treatment market, by distribution channel, 2018 - 2030 (USD Billion)
  • Table 61 South Korea cerebral infarction treatment market, by drug class, 2018 - 2030 (USD Billion)
  • Table 62 South Korea cerebral infarction treatment market, by type, 2018 - 2030 (USD Billion)
  • Table 63 South Korea cerebral infarction treatment market, by distribution channel, 2018 - 2030 (USD Billion)
  • Table 64 Australia cerebral infarction treatment market, by drug class, 2018 - 2030 (USD Billion)
  • Table 65 Australia cerebral infarction treatment market, by type, 2018 - 2030 (USD Billion)
  • Table 66 Australia cerebral infarction treatment market, by distribution channel, 2018 - 2030 (USD Billion)
  • Table 67 Thailand cerebral infarction treatment market, by drug class, 2018 - 2030 (USD Billion)
  • Table 68 Thailand cerebral infarction treatment market, by type, 2018 - 2030 (USD Billion)
  • Table 69 Thailand cerebral infarction treatment market, by distribution channel, 2018 - 2030 (USD Billion)
  • Table 70 Latin America cerebral infarction treatment market, by country, 2018 - 2030 (USD Billion)
  • Table 71 Latin America cerebral infarction treatment market, by drug class, 2018 - 2030 (USD Billion)
  • Table 72 Latin America cerebral infarction treatment market, by type, 2018 - 2030 (USD Billion
  • Table 73 Latin America cerebral infarction treatment market, by distribution channel, 2018 - 2030 (USD Billion
  • Table 74 Brazil cerebral infarction treatment market, by drug class, 2018 - 2030 (USD Billion)
  • Table 75 Brazil cerebral infarction treatment market, by type, 2018 - 2030 (USD Billion)
  • Table 76 Brazil cerebral infarction treatment market, by distribution channel, 2018 - 2030 (USD Billion)
  • Table 77 Argentina cerebral infarction treatment market, by drug class, 2018 - 2030 (USD Billion)
  • Table 78 Argentina cerebral infarction treatment market, by type, 2018 - 2030 (USD Billion)
  • Table 79 Argentina cerebral infarction treatment market, by distribution channel, 2018 - 2030 (USD Billion)
  • Table 80 Middle East & Africa cerebral infarction treatment market, by country, 2018 - 2030 (USD Billion)
  • Table 81 Middle East & Africa cerebral infarction treatment market, by drug class, 2018 - 2030 (USD Billion)
  • Table 82 Middle East & Africa cerebral infarction treatment market, by type, 2018 - 2030 (USD Billion)
  • Table 83 Middle East & Africa cerebral infarction treatment market, by distribution channel, 2018 - 2030 (USD Billion)
  • Table 84 South Africa cerebral infarction treatment market, by drug class, 2018 - 2030 (USD Billion)
  • Table 85 South Africa cerebral infarction treatment market, by type, 2018 - 2030 (USD Billion)
  • Table 86 South Africa cerebral infarction treatment market, by distribution channel, 2018 - 2030 (USD Billion)
  • Table 87 Saudi Arabia cerebral infarction treatment market, by drug class, 2018 - 2030 (USD Billion)
  • Table 88 Saudi Arabia cerebral infarction treatment market, by type, 2018 - 2030 (USD Billion)
  • Table 89 Saudi Arabia cerebral infarction treatment market, by distribution channel, 2018 - 2030 (USD Billion)
  • Table 90 UAE cerebral infarction treatment market, by drug class, 2018 - 2030 (USD Billion)
  • Table 91 UAE cerebral infarction treatment market, by type, 2018 - 2030 (USD Billion)
  • Table 92 UAE cerebral infarction treatment market, by distribution channel, 2018 - 2030 (USD Billion)
  • Table 93 Kuwait cerebral infarction treatment market, by drug class, 2018 - 2030 (USD Billion)
  • Table 94 Kuwait cerebral infarction treatment market, by type, 2018 - 2030 (USD Billion)
  • Table 95 Kuwait cerebral infarction treatment market, by distribution channel, 2018 - 2030 (USD Billion)

List of Figures

  • Fig. 1 Cerebral infarction treatment market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Drug class outlook (USD Billion)
  • Fig. 10 Type outlook (USD Billion)
  • Fig. 11 Distribution channel outlook (USD Billion)
  • Fig. 12 Competitive landscape
  • Fig. 13 Cerebral infarction treatment market dynamics
  • Fig. 14 Cerebral infarction treatment market: Porter's five forces analysis
  • Fig. 15 Cerebral infarction treatment market: PESTLE analysis
  • Fig. 16 Cerebral infarction treatment market: Drug class segment dashboard
  • Fig. 17 Cerebral infarction treatment market: Drug class market share analysis, 2024 & 2030
  • Fig. 18 Tissue plasminogen activators (tPA) market, 2018 - 2030 (USD Billion)
  • Fig. 19 Anticoagulants market, 2018 - 2030 (USD Billion)
  • Fig. 20 Antiplatelets market, 2018 - 2030 (USD Billion)
  • Fig. 21 Anticonvulsants market, 2018 - 2030 (USD Billion)
  • Fig. 22 Others market, 2018 - 2030 (USD Billion)
  • Fig. 23 Cerebral infarction treatment market: Type segment dashboard
  • Fig. 24 Cerebral infarction treatment market: Type market share analysis, 2024 & 2030
  • Fig. 25 Ischemic stroke market, 2018 - 2030 (USD Billion)
  • Fig. 26 Hemorrhagic stroke market, 2018 - 2030 (USD Billion)
  • Fig. 27 Cerebral infarction treatment market: Distribution channel segment dashboard
  • Fig. 28 Cerebral infarction treatment market: Distribution channel market share analysis, 2024 & 2030
  • Fig. 29 Hospital pharmacies market, 2018 - 2030 (USD Billion)
  • Fig. 30 Retail pharmacies market, 2018 - 2030 (USD Billion)
  • Fig. 31 Other market, 2018 - 2030 (USD Billion)
  • Fig. 32 Cerebral infarction treatment market revenue, by region
  • Fig. 33 Regional marketplace: Key takeaways
  • Fig. 34 North America cerebral infarction treatment market, 2018 - 2030 (USD Billion)
  • Fig. 35 U.S. country dynamics
  • Fig. 36 U.S. cerebral infarction treatment market, 2018 - 2030 (USD Billion)
  • Fig. 37 Canada country dynamics
  • Fig. 38 Canada cerebral infarction treatment market, 2018 - 2030 (USD Billion)
  • Fig. 39 Mexico country dynamics
  • Fig. 40 Mexico cerebral infarction treatment market, 2018 - 2030 (USD Billion)
  • Fig. 41 Europe cerebral infarction treatment market, 2018 - 2030 (USD Billion)
  • Fig. 42 UK country dynamics
  • Fig. 43 UK cerebral infarction treatment market, 2018 - 2030 (USD Billion)
  • Fig. 44 Germany country dynamics
  • Fig. 45 Germany cerebral infarction treatment market, 2018 - 2030 (USD Billion)
  • Fig. 46 France country dynamics
  • Fig. 47 France cerebral infarction treatment market, 2018 - 2030 (USD Billion)
  • Fig. 48 Italy country dynamics
  • Fig. 49 Italy cerebral infarction treatment market, 2018 - 2030 (USD Billion)
  • Fig. 50 Spain country dynamics
  • Fig. 51 Spain cerebral infarction treatment market, 2018 - 2030 (USD Billion)
  • Fig. 52 Denmark country dynamics
  • Fig. 53 Denmark cerebral infarction treatment market, 2018 - 2030 (USD Billion)
  • Fig. 54 Sweden country dynamics
  • Fig. 55 Sweden cerebral infarction treatment market, 2018 - 2030 (USD Billion)
  • Fig. 56 Norway country dynamics
  • Fig. 57 Norway cerebral infarction treatment market, 2018 - 2030 (USD Billion)
  • Fig. 58 Asia Pacific cerebral infarction treatment market, 2018 - 2030 (USD Billion)
  • Fig. 59 Japan country dynamics
  • Fig. 60 Japan cerebral infarction treatment market, 2018 - 2030 (USD Billion)
  • Fig. 61 China country dynamics
  • Fig. 62 China cerebral infarction treatment market, 2018 - 2030 (USD Billion)
  • Fig. 63 India country dynamics
  • Fig. 64 India cerebral infarction treatment market, 2018 - 2030 (USD Billion)
  • Fig. 65 South Korea country dynamics
  • Fig. 66 South Korea cerebral infarction treatment market, 2018 - 2030 (USD Billion)
  • Fig. 67 Australia country dynamics
  • Fig. 68 Australia cerebral infarction treatment market, 2018 - 2030 (USD Billion)
  • Fig. 69 Thailand country dynamics
  • Fig. 70 Thailand cerebral infarction treatment market, 2018 - 2030 (USD Billion)
  • Fig. 71 Latin America cerebral infarction treatment market, 2018 - 2030 (USD Billion)
  • Fig. 72 Brazil country dynamics
  • Fig. 73 Brazil cerebral infarction treatment market, 2018 - 2030 (USD Billion)
  • Fig. 74 Argentina country dynamics
  • Fig. 75 Argentina cerebral infarction treatment market, 2018 - 2030 (USD Billion)
  • Fig. 76 MEA cerebral infarction treatment market, 2018 - 2030 (USD Billion)
  • Fig. 77 South Africa country dynamics
  • Fig. 78 South Africa cerebral infarction treatment market, 2018 - 2030 (USD Billion)
  • Fig. 79 Saudi Arabia country dynamics
  • Fig. 80 Saudi Arabia cerebral infarction treatment market, 2018 - 2030 (USD Billion)
  • Fig. 81 UAE country dynamics
  • Fig. 82 UAE cerebral infarction treatment market, 2018 - 2030 (USD Billion)
  • Fig. 83 Kuwait country dynamics
  • Fig. 84 Kuwait cerebral infarction treatment market, 2018 - 2030 (USD Billion)
  • Fig. 85 Company categorization
  • Fig. 86 Company market position analysis
  • Fig. 87 Strategic framework
目次
Product Code: GVR-4-68040-450-8

Cerebral Infarction Treatment Market Growth & Trends:

The global cerebral infarction treatment market size is expected to reach USD 20.51 billion by 2030 and is projected to grow at a CAGR of 7.4% from 2025 to 2030, according to a new report by Grand View Research, Inc. The growing prevalence of ischemic strokes, driven by an aging global population and increasing rates of lifestyle-related risk factors such as hypertension and diabetes, is a key factor in the expansion of the cerebral infarction treatment market.

According to a study published by the National Library of Medicine in March 2023, hemorrhagic stroke accounts for 10.0% to 20.0% of all strokes annually. The incidence varies significantly by region, with 8.0%-15.0% in the U.S., the UK, and Australia, and 18.0% to 24.0% in Japan and Korea. The rate of hemorrhagic stroke is notably higher in low- and middle-income countries, and among Asians. Furthermore, while stroke incidence is higher in men and increases with age, the global burden of hemorrhagic stroke is rising, particularly in African and Asian countries. Effective management of hypertension has been shown to reduce the incidence of intracerebral hemorrhage (ICH), though the fatality rate remains a concern, ranging from 25.0% to 30.0% in high-income countries and 30% to 48% in lower-income regions, highlighting disparities in critical care efficacy.

Technological advancements are significantly enhancing the treatment landscape for cerebral infarction. Innovations in thrombolytic therapies, such as tissue plasminogen activators (tPA), and development of mechanical thrombectomy devices have markedly improved patient outcomes. Moreover, the integration of artificial intelligence (AI) into diagnostic and treatment processes is revolutionizing stroke care. AI-driven algorithms now play a crucial role in predicting stroke risk and tailoring treatment strategies, which helps in personalizing care and improving overall efficacy. These advancements are not only improving the precision of treatments but also contributing to the broader adoption of advanced therapeutic options. Combined with increased investment in research and development, these technological strides are expected to drive significant growth in the cerebral infarction treatment market.

Cerebral Infarction Treatment Market Report Highlights:

  • In 2024, the ischemic stroke segment held the largest share of 78.6% due to its high prevalence, technological advancements, and growing awareness of early intervention
  • The tissue plasminogen activators (tPA) segment secured the largest revenue share of 39.2% in 2024, driven by its proven efficacy, widespread use, and crucial role in treating ischemic strokes
  • In 2024, the hospital pharmacies segment dominated the cerebral infarction treatment market, capturing a substantial revenue share of 63.6%

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Drug Class
    • 1.2.2. Type
    • 1.2.3. Distribution Channel
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Cerebral Infarction Treatment Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrants
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis

Chapter 4. Cerebral Infarction Treatment Market: Drug Class Business Analysis

  • 4.1. Drug Class Market Share, 2024 & 2030
  • 4.2. Drug Class Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Drug Class, 2018 to 2030 (USD Billion)
  • 4.4. Tissue Plasminogen Activators (tPA)
    • 4.4.1. Tissue Plasminogen Activators (tPA) Market, 2018 - 2030 (USD Billion)
  • 4.5. Anticoagulants
    • 4.5.1. Anticoagulants Market, 2018 - 2030 (USD Billion)
  • 4.6. Antiplatelets
    • 4.6.1. Antiplatelets Market, 2018 - 2030 (USD Billion)
  • 4.7. Anticonvulsants
    • 4.7.1. Anticonvulsants Market, 2018 - 2030 (USD Billion)
  • 4.8. Others
    • 4.8.1. Others Market, 2018 - 2030 (USD Billion)

Chapter 5. Cerebral Infarction Treatment Market: Type Business Analysis

  • 5.1. Type Market Share, 2024 & 2030
  • 5.2. Type Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by Type, 2018 to 2030 (USD Billion)
  • 5.4. Ischemic Stroke
    • 5.4.1. Ischemic Stroke Market, 2018 - 2030 (USD Billion)
  • 5.5. Hemorrhagic Stroke
    • 5.5.1. Hemorrhagic Stroke Market, 2018 - 2030 (USD Billion)

Chapter 6. Cerebral Infarction Treatment Market: Distribution Channel Business Analysis

  • 6.1. Distribution Channel Market Share, 2024 & 2030
  • 6.2. Distribution Channel Segment Dashboard
  • 6.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2018 to 2030 (USD Billion)
  • 6.4. Hospital Pharmacies
    • 6.4.1. Hospital Pharmacies Market, 2018 - 2030 (USD Billion)
  • 6.5. Retail Pharmacies
    • 6.5.1. Retail Pharmacies Market, 2018 - 2030 (USD Billion)
  • 6.6. Other
    • 6.6.1. Other Market, 2018 - 2030 (USD Billion)

Chapter 7. Cerebral Infarction Treatment Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Market Share Analysis, 2024 & 2030
  • 7.2. Regional Market Dashboard
  • 7.3. Market Size & Forecasts Trend Analysis, 2018 to 2030:
  • 7.4. North America
    • 7.4.1. North America Cerebral Infarction Treatment Market Estimates and Forecasts, by Country, 2018 - 2030 (USD Billion)
    • 7.4.2. U.S.
      • 7.4.2.1. Key Country Dynamics
      • 7.4.2.2. Regulatory Framework
      • 7.4.2.3. Competitive Insights
      • 7.4.2.4. U.S. Cerebral Infarction Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.4.3. Canada
      • 7.4.3.1. Key Country Dynamics
      • 7.4.3.2. Regulatory Framework
      • 7.4.3.3. Competitive Insights
      • 7.4.3.4. Canada Cerebral Infarction Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.4.4. Mexico
      • 7.4.4.1. Key Country Dynamics
      • 7.4.4.2. Regulatory Framework
      • 7.4.4.3. Competitive Insights
      • 7.4.4.4. Mexico Cerebral Infarction Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.5. Europe
    • 7.5.1. Europe Cerebral Infarction Treatment Market Estimates and Forecasts, by Country, 2018 - 2030 (USD Billion)
    • 7.5.2. UK
      • 7.5.2.1. Key Country Dynamics
      • 7.5.2.2. Regulatory Framework
      • 7.5.2.3. Competitive Insights
      • 7.5.2.4. UK Cerebral Infarction Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.5.3. Germany
      • 7.5.3.1. Key Country Dynamics
      • 7.5.3.2. Regulatory Framework
      • 7.5.3.3. Competitive Insights
      • 7.5.3.4. Germany Cerebral Infarction Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.5.4. France
      • 7.5.4.1. Key Country Dynamics
      • 7.5.4.2. Regulatory Framework
      • 7.5.4.3. Competitive Insights
      • 7.5.4.4. France Cerebral Infarction Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.5.5. Italy
      • 7.5.5.1. Key Country Dynamics
      • 7.5.5.2. Regulatory Framework
      • 7.5.5.3. Competitive Insights
      • 7.5.5.4. Italy Cerebral Infarction Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.5.6. Spain
      • 7.5.6.1. Key Country Dynamics
      • 7.5.6.2. Regulatory Framework
      • 7.5.6.3. Competitive Insights
      • 7.5.6.4. Spain Cerebral Infarction Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.5.7. Denmark
      • 7.5.7.1. Key Country Dynamics
      • 7.5.7.2. Regulatory Framework
      • 7.5.7.3. Competitive Insights
      • 7.5.7.4. Denmark Cerebral Infarction Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.5.8. Sweden
      • 7.5.8.1. Key Country Dynamics
      • 7.5.8.2. Regulatory Framework
      • 7.5.8.3. Competitive Insights
      • 7.5.8.4. Sweden Cerebral Infarction Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.5.9. Norway
      • 7.5.9.1. Key Country Dynamics
      • 7.5.9.2. Regulatory Framework
      • 7.5.9.3. Competitive Insights
      • 7.5.9.4. Norway Cerebral Infarction Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.6. Asia Pacific
    • 7.6.1. Asia Pacific Cerebral Infarction Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.6.2. Japan
      • 7.6.2.1. Key Country Dynamics
      • 7.6.2.2. Regulatory Framework
      • 7.6.2.3. Competitive Insights
      • 7.6.2.4. Japan Cerebral Infarction Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.6.3. China
      • 7.6.3.1. Key Country Dynamics
      • 7.6.3.2. Regulatory Framework
      • 7.6.3.3. Competitive Insights
      • 7.6.3.4. China Cerebral Infarction Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.6.4. India
      • 7.6.4.1. Key Country Dynamics
      • 7.6.4.2. Regulatory Framework
      • 7.6.4.3. Competitive Insights
      • 7.6.4.4. India Cerebral Infarction Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.6.5. South Korea
      • 7.6.5.1. Key Country Dynamics
      • 7.6.5.2. Regulatory Framework
      • 7.6.5.3. Competitive Insights
      • 7.6.5.4. South Korea Cerebral Infarction Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.6.6. Australia
      • 7.6.6.1. Key Country Dynamics
      • 7.6.6.2. Regulatory Framework
      • 7.6.6.3. Competitive Insights
      • 7.6.6.4. Australia Cerebral Infarction Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.6.7. Thailand
      • 7.6.7.1. Key Country Dynamics
      • 7.6.7.2. Regulatory Framework
      • 7.6.7.3. Competitive Insights
      • 7.6.7.4. Thailand Cerebral Infarction Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.7. Latin America
    • 7.7.1. Latin America Cerebral Infarction Treatment Market Estimates and Forecasts, by Country, 2018 - 2030 (USD Billion)
    • 7.7.2. Brazil
      • 7.7.2.1. Key Country Dynamics
      • 7.7.2.2. Regulatory Framework
      • 7.7.2.3. Competitive Insights
      • 7.7.2.4. Brazil Cerebral Infarction Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.7.3. Argentina
      • 7.7.3.1. Key Country Dynamics
      • 7.7.3.2. Regulatory Framework
      • 7.7.3.3. Competitive Insights
      • 7.7.3.4. Argentina Cerebral Infarction Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.8. MEA
    • 7.8.1. MEA Cerebral Infarction Treatment Market Estimates and Forecasts, by Country, 2018 - 2030 (USD Billion)
    • 7.8.2. South Africa
      • 7.8.2.1. Key Country Dynamics
      • 7.8.2.2. Regulatory Framework
      • 7.8.2.3. Competitive Insights
      • 7.8.2.4. South Africa Cerebral Infarction Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.8.3. Saudi Arabia
      • 7.8.3.1. Key Country Dynamics
      • 7.8.3.2. Regulatory Framework
      • 7.8.3.3. Competitive Insights
      • 7.8.3.4. Saudi Arabia Cerebral Infarction Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.8.4. UAE
      • 7.8.4.1. Key Country Dynamics
      • 7.8.4.2. Regulatory Framework
      • 7.8.4.3. Competitive Insights
      • 7.8.4.4. UAE Cerebral Infarction Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.8.5. Kuwait
      • 7.8.5.1. Key Country Dynamics
      • 7.8.5.2. Regulatory Framework
      • 7.8.5.3. Competitive Insights
      • 7.8.5.4. Kuwait Cerebral Infarction Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)

Chapter 8. Competitive Landscape

  • 8.1. Participant Overview
  • 8.2. Company Market Position Analysis
  • 8.3. Company Categorization
  • 8.4. Strategy Mapping
  • 8.5. Company Profiles/Listing
    • 8.5.1. Amgen Inc.
      • 8.5.1.1. Overview
      • 8.5.1.2. Financial Performance
      • 8.5.1.3. Product Benchmarking
      • 8.5.1.4. Strategic Initiatives
    • 8.5.2. Pfizer Inc.
      • 8.5.2.1. Overview
      • 8.5.2.2. Financial Performance
      • 8.5.2.3. Product Benchmarking
      • 8.5.2.4. Strategic Initiatives
    • 8.5.3. Novartis AG
      • 8.5.3.1. Overview
      • 8.5.3.2. Financial Performance
      • 8.5.3.3. Product Benchmarking
      • 8.5.3.4. Strategic Initiatives
    • 8.5.4. Amneal Pharmaceuticals LLC
      • 8.5.4.1. Overview
      • 8.5.4.2. Financial Performance
      • 8.5.4.3. Product Benchmarking
      • 8.5.4.4. Strategic Initiatives
    • 8.5.5. Sanofi
      • 8.5.5.1. Overview
      • 8.5.5.2. Financial Performance
      • 8.5.5.3. Product Benchmarking
      • 8.5.5.4. Strategic Initiatives
    • 8.5.6. Abbott
      • 8.5.6.1. Overview
      • 8.5.6.2. Financial Performance
      • 8.5.6.3. Product Benchmarking
      • 8.5.6.4. Strategic Initiatives
    • 8.5.7. Johnson & Johnson Services, Inc.
      • 8.5.7.1. Overview
      • 8.5.7.2. Financial Performance
      • 8.5.7.3. Product Benchmarking
      • 8.5.7.4. Strategic Initiatives
    • 8.5.8. Bristol-Myers Squibb Company
      • 8.5.8.1. Overview
      • 8.5.8.2. Financial Performance
      • 8.5.8.3. Product Benchmarking
      • 8.5.8.4. Strategic Initiatives
    • 8.5.9. DAIICHI SANKYO COMPANY
      • 8.5.9.1. Overview
      • 8.5.9.2. Financial Performance
      • 8.5.9.3. Product Benchmarking
      • 8.5.9.4. Strategic Initiatives
    • 8.5.10. Otsuka Holdings Co., Ltd.
      • 8.5.10.1. Overview
      • 8.5.10.2. Financial Performance
      • 8.5.10.3. Product Benchmarking
      • 8.5.10.4. Strategic Initiatives